INTRODUCTION
============

Dermatomyositis (DM) is an autoimmune inflammatory myopathy characterized by muscle weakness of the limbs, mainly proximal, symmetric, and progressive, in addition to classic cutaneous alterations such as heliotrope rash and Gottron's papules. It can also present other skin lesions such as cuticular hypertrophy, periungual hyperemia, photosensitivity, calcinosis, "V-neck sign", and "shawl sign", among others.^[@r1]-[@r3]^

In 10-15% of cases, DM patients do not present muscle involvement, thus characterizing the DM subset known as amyopathic or *sine myositis*.^[@r4],[@r5]^ DM can also be classified as hypomyopathic, with altered laboratory results, evidencing some degree of myopathy. These two forms of DM (amyopathic and hypomyopathic) are called clinically amyopathic DM.^[@r2],[@r5]^

Sato *et al.*^[@r6]^ identified the autoantibody to the 140-kDa clinically amyopathic dermatomyositis peptide (CADM-140) in Japanese patients with clinically amyopathic DM and whose principal characteristic was rapidly progressive pulmonary involvement. The target antigen for this autoantibody is the 140-kDa cytoplasmic protein called melanoma differentiation associated gene 5 (MDA-5), an RNA-specific helicase.^[@r7]^ Therefore, anti-CADM-140 is now also referred to as anti-MDA-5.^[@r7]^

The clinical characteristics and prognosis of patients with anti-MDA-5 autoantibodies are variable. The literature mentions the relationship between anti-MDA-5 and skin eruptions, rapid and progressive development of interstitial lung disease, skin lesions (rash, palmar papules, and/or ulcerations), joint and lung involvement, and/or worse prognosis in DM patients.^[@r7]-[@r13]^ Some of these patients also presented a similar phenotype to that of anti-synthetase syndrome.^[@r14]^ However, this wide phenotypical variability between the studies on the association with anti-MDA-5 autoantibody may be due to the heterogeneity of the populations studied, thus justifying the importance of assessing Brazilian patients with idiopathic inflammatory myopathies.

These studies also failed to mention possible confounders (smoking, chronic obstructive pulmonary disease, and overlapping of other systemic autoimmune diseases such as systemic sclerosis, systemic lupus erythematosus, and Sjögren's syndrome, among others), which could interfere in the correlation between anti-MDA-5 autoantibody and the patients' clinical and laboratory parameters.^[@r8],[@r10]-[@r16]^

Presence of anti-MDA-5 autoantibody had not been analyzed previously in Brazilian patients with DM, thus justifying the current study, with the aim of verifying the autoantibody's prevalence in patients with DM and clinically amyopathic DM, without possible confounders. The study also aimed to assess a possible association between the autoantibody and demographic, clinical, laboratory, and imaging parameters.

METHODS
=======

This was a single-center cross-sectional study to evaluate the presence of anti-MDA-5 autoantibody in adult patients with DM, defined according to the criteria proposed by Bohan and Peter.^[@r1]^ Clinically amyopathic DM was determined according to the criteria of Gerami *et al.*^[@r16]^ All the assessed patients came from the same tertiary service, from 2000 to 2016.

The study was approved by the local Institutional Review Board (number 1.483.411).

The exclusion criteria were: patients with *overlapping systemic autoimmune diseases,* neoplasms, pulmonary infections (tuberculosis, aspergilloma), or chronic obstructive pulmonary disease; history of smoking; history of prior exposure to statins or fibrates; and suspected cases of muscular dystrophies.

Of the 218 patients that were initially admitted, 87 were excluded after application of the exclusion criteria. We thus analyzed 131 consecutive cases, of which 109 (83.2%) were DM and 22 (16.8%) clinically amyopathic DM.

The following data from the eligible patients were assessed, based on the electronic patient files, with pre-standardized and parameterized information, covering the data from the initial diagnostic workup and follow-up of patients with clinical and laboratory activity:

1.  Demographics: current age; age at diagnosis of the disease; time between diagnosis and onset of symptoms; sex and race/color;

2.  Clinical manifestations: constitutional symptoms (fever and weight loss); heliotrope rash; Gottron's sign/papules; facial rash; "V-neck sign"; "shawl sign"; periungual hyperemia; vasculitis; calcinosis; ulcers; Raynaud's phenomenon; mechanic's hands; muscle weakness in the upper and lower limbs; *Medical Research Council* muscle strength grading; joint, gastrointestinal (high dysphagia), and pulmonary involvement (dyspnea: on moderate to small efforts; rapidly evolving dyspnea: in less than three months since onset of general symptoms);^[@r17]^

3.  Altered pulmonary images obtained by CT: incipient lung disease, "ground glass" opacity, and bilateral basal pulmonary fibrosis;

4.  Serum muscle enzyme levels in routine blood samples taken for medical consultation: creatinine phosphokinase (reference value: 32 - 294U/L) and aldolase (1.0 - 7.5U/L), performed with automated kinetic method.

Analysis of anti-MDA-5 autoantibody used serum samples in aliquots previously stored at -20ºC, collected during the initial workup in patients with clinical and laboratory activity. The autoantibody was identified with *enzyme-linked immunosorbent assay* (ELISA), through the MDA-5 recombinant protein and anti-MDA-5 monoclonal antibody (MyBioSource, CA, USA). For the purposes of this study and to ensure positive results for anti-MDA-5, positivity was defined as patients with values more than three standard deviations above the mean in eight controls.

Statistical analysis
--------------------

The Kolmogorov-Smirnov test was used to assess the distribution of each of the continuous variables. The results were presented as mean ±standard deviation for continuous variables and number (%) for categorical variables. Median values (interquartile range, 25% - 75%) were calculated for continuous variables that did not display normal distribution. Data on presence versus absence of anti-MDA-5 autoantibody were compared with Students t-test or Mann-Whitney test for continuous variables. Differences in categorical variables were calculated with Pearsons c^[@r2]^ or Fisher's exact test. Statistical significance was set at *p*\<0.05.

RESULTS
=======

Of the 131 patients, 108 (83.2%) and 22 (16.8%) presented DM and clinically amyopathic DM, respectively. [Table 1](#t1){ref-type="table"} shows these patients' demographic, clinical, laboratory, and imaging data Age at diagnosis was 41.3 and 49.7 years, respectively, in patients with DM and clinically amyopathic DM. Female gender and white color predominated in both groups.

###### 

Demographic, clinical, laboratory, and imaging data of patients with dermatomyositis (classic and clinically amyopathic forms)

                                                 DM (N=109)        CADM (N=22)      TOTAL (N=131)
  ---------------------------------------------- ----------------- ---------------- ------------------
  Age at diagnosis (years)                       41.3±14.4         49.7 ±14.7       41.3±14.4
  Time between diagnosis and symptoms (months)   4 (2-7)           4 (2-12)         6 (0-36)
  Female                                         84 (77.1)         12 (54.6)        96 (73.3)
  White                                          91 (83.5)         18 (81.8)        109 (83.2)
  Constitutional symptoms                        69 (63.3)         12 (54.6)        81 (61.8)
  Cutaneous                                                                          
      Heliotrope rash                            92 (84.4)         19 (86.4)        111 (84.7)
      Gottron\'s sign/papules                    98 (89.9)         21 (95.5)        119 (90.8)
      Facial rash                                69 (63.3)         16 (72.7)        85 (64.9)
      \"V-neck\" sign                            47 (43.1)         10 (45.5)        57 (43.5)
      \"Shawl\" sign                             30 (27.5)         6 (27.3)         36 (27.5)
      Periungual hyperemia                       67 (61.5)         17 (77.3)        84 (64.1)
      Vasculitis                                 26 (23.9)         8 (36.4)         34 (26.0)
      Calcinosis                                 10 (9.2)          2 (9.1)          12 (9.2)
      Mechanic\'s hands                          22 (20.2)         3 (13.6)         25 (19.1)
      Ulcers                                     19 (17.4)         5 (22.7)         24 (18.3)
      Raynaud\'s phenomenon                      52 (47.7)         13 (59.1)        65 (49.6)
  Muscle weakness                                                                    
      Upper limbs                                                                    
       Grade V                                   1 (0.9)           15 (68.2)        16 (12.2)
       Grade IV                                  69 (63.3)         7 (31.8)         76 (58.0)
       Grade III                                 39 (35.8)         0                39 (29.8)
       Grade II                                  0                 0                0
       Grade I                                   0                 0                0
      Lower limbs                                                                    
       Grade V                                   2 (1.8)           14 (63.6)        16 (12.2)
       Grade IV                                  74 (67.9)         8 (36.4)         82 (62.6)
       Grade III                                 31 (28.4)         0                31 (23.7)
       Grade II                                  2 (1.8)           0                2 (1.5)
       Grade I                                   0                 0                0
  Joint                                          31 (28.4)         9 (40.9)         40 (30.5)
  Gastrointestinal (dysphagia)                   59 (54.1)         5 (22.7)         64 (48.9)
  Pulmonary                                                                          
      Dyspnea                                    33 (30.3)         7 (31.8)         40 (30.5)
      Dyspnea (\< 3 months)                      15 (13.8)         1 (4.6)          16 (12.2)
  Chest CT                                                                           
      \"Ground glass\"                           15 (13.8)         5 (22.7)         20 (15.3)
      Incipient lung disease                     33 (30.3)         7 (31.8)         40 (30.5)
      Pulmonary fibrosis                         8 (7.3)           1 (4.6)          9 (6.9)
  Creatine phosphokinase (U/L)                   1831 (29-8000)    110 (124-170)    4435 (28-22858)
  Aldolase (U/L)                                 24.7 (8.3-60.8)   9.7 (5.5-15.3)   51.2 (2.9-415.5)
  Anti-MDA-5                                     16 (14.7)         5 (22.7)         21 (16.0)

CADM: Clinically amyopathic dermatomyositis; MDA: melanoma differentiation-associated gene 5.

Data expressed as mean ± standard deviation, median (interquartile range 25% -75%), or percentage (%).

Constitutional symptoms were present in more than half of the cases in both groups ([Table 1](#t1){ref-type="table"}).

The principal cutaneous manifestations were heliotrope rash and Gottron's sign/papules, followed by secondary lesions (facial rash, "V-neck" sign, "shawl" sign, periungual hyperemia, vasculitis, calcinosis, mechanic's hand, ulcers, and Raynaud's phenomenon).

As expected, muscle weakness in the limbs and elevated serum muscle enzymes were more evident in the classic form of DM, compared to clinically amyopathic DM.

Joint involvement and dysphagia were also found in both groups.

Dyspnea was reported in 30.3% and 31.8% of patients with DM and clinically amyopathic DM, respectively, while rapidly evolving dyspnea was present in 13.8% and 4.6% of the patients. In addition, the main CT finding was presence of incipient lung disease in both groups (one third of cases).

The anti-MDA-5 autoantibody was present in 14.7% of patients with DM and 22.7% of these with clinically amyopathic DM ([Table 1](#t1){ref-type="table"}).

We also compared patients with DM (classic form) according to presence or absence of anti-MDA-5 autoantibody \[MDA-5(+) *vs*. MDA-5(-)\] ([Table 2](#t2){ref-type="table"}). Age, gender, race/color, and time between diagnosis and onset of simptoms were similar in the two groups. The presence of constitutional symptoms, clinical manifestations, and laboratory and imaging results were also comparable between the two groups, except for the lower frequency of periungual hyperemia (25% *vs*. 67.7%; p\<0.002) and Raynaud's phenomenon (18.8% *vs*. 52.7%; p\<0.015) in anti-MDA-5(+) compared to anti-MDA-5 (-) patients.

###### 

Demographic, clinical, laboratory, and imaging data from patients with dermatomyositis (classic from) in relation to anti-MDA-5 autoantibody positivity

                                                 MDA-5 (+) (N=16)   MDA-5 (-) (N=93)   p-value
  ---------------------------------------------- ------------------ ------------------ ---------
  Age at diagnosis (years)                       41.8±14.0          40.5±14.5          0.749
  Time between diagnosis and symptoms (months)   3 (1-5)            4 (3-7)            0.067
  Female                                         13 (81.2)          71 (76.3)          1.000
  White                                          15 (93.8)          76 (81.7)          1.000
  Constitutional symptoms                        11 (68.8)          58 (62.4)          0.782
  Cutaneous                                                                             
      Heliotrope rash                            13 (81.3)          79 (85.0)          0.713
      Gottron\'s sign/papules                    14 (87.5)          84 (90.3)          0.663
      Facial rash                                11 (68.8)          58 (62.4)          0.781
      \"V-neck\" sign                            5 (31.3)           42 (45.2)          0.414
      \"Shawl\" sign                             1 (6.3)            29 (31.2)          0.065
      Periungual hyperemia                       4 (25.0)           63 (67.7)          0.002
      Vasculitis                                 4 (25.0)           22 (23.7)          1.000
      Calcinosis                                 1 (6.3)            9 (9.7)            1.000
      Mechanic\'s hands                          1 (6.3)            21 (22.6)          0.185
      Ulcers                                     4 (25.0)           15 (16.1)          0.474
      Raynaud\'s phenomenon                      3 (18.8)           49 (52.7)          0.015
  Muscle weakness                                                                       
      Upper limbs                                                                       
       Grade V                                   0                  1 (1.1)             
       Grade IV                                  3 (18.8)           66 (71.0)           
       Grade III                                 13 (81.2)          26 (27.9)          0.827
       Grade II                                  0                  0                   
       Grade I                                   0                  0                   
      Lower limbs                                                                       
       Grade V                                   1 (6.3)            1 (1.1)             
       Grade IV                                  10 (62.4)          64 (68.7)           
       Grade III                                 5 (31.3)           26 (28.0)          0.733
       Grade II                                  0                  2 (2.2)             
       Grade I                                   0                  0                   
  Join                                           5 (31.3)           26 (28.0)          0.771
  Gastrointestinal (dysphagia)                   6 (37.5)           53 (57.0)          0.180
  Pulmonary                                                                             
      Dyspnea                                    4 (25.0)           29 (31.2)          0.772
      Dyspnea (\< 3 months)                      2 (12.5)           13 (14.0)          1.000
      Chest CT                                                                          
       \"Ground glass\"                          1 (6.3)            14 (15.1)          0.693
       Incipient lung disease                    4 (25.0)           29 (31.2)          0.772
       Pulmonary fibrosis                        0                  8 (8.6)            \-
      Creatine Phosphokinase (U/L)               3726 (440-5884)    1341 (340-8067)    0.783
      Aldolase (U/L)                             39.6 (6.3-60.8)    23.4 (8.4-68.9)    0.975

MDA: melanoma differentiation-associated gene 5.

Data expressed as mean ± standard deviation, median (interquartile range 25% -75%), or percentage (%).

In patients with clinically amyopathic DM, all the demographic, clinical, laboratory, and imaging parameters were similar in those with MDA-5(+) and MDA-5(-) ([Table 3](#t3){ref-type="table"}).

###### 

Demographic, clinical, laboratory, and imaging data from patients with clinically amyopathic dermatomyositis in relation to anti-MDA-5 autoantibody positivity

                                                 MDA-5 (+) (N=5)    MDA-5 (-) (N=17)   Valor de *p*
  ---------------------------------------------- ------------------ ------------------ --------------
  Age at diagnosis (years)                       44.2±15.5          44.0±13.5          0.981
  Time between diagnosis and symptoms (months)   3 (1-8)            5 (3-18)           0.359
  Female                                         2 (40.0)           10 (58.8)          0.624
  White                                          4 (80.0)           14 (82.4)          1.000
  Constitutional symptoms                        3 (60.0)           9 (52.9)           1.000
  Cutaneous                                                                             
      Heliotrope rash                            4 (80.0)           15 (88.2)          1.000
      Gottron\'s sign/papules                    5 (100.0)          16 (94.1)          0.455
      Facial rash                                3 (60.0)           13 (76.5)          0.585
      \"V-neck\"sign                             0                  10 (58.8)          \-
      \"Shawl\" sign                             0                  6 (35.3)           \-
       Periungual hyperemia                      5 (100)            12 (70.6)          0.290
      Vasculitis                                 2 (40.0)           6 (35.3)           1.000
      Calcinosis                                 0                  2 (11.8)           \-
      Mechanic\'s hands                          1 (20.0)           2 (11.8)           1.000
      Ulcers                                     1 (20.0)           4 (23.5)           1.000
      Raynaud\'s phenomenon                      2 (40.0)           11 (64.7)          0.609
  Muscle weakness                                                                       
      Upper limbs                                                                       
       Grade V                                   2 (40.0)           13 (76.5)           
       Grade IV                                  3 (60.0)           4 (23.5)            
       Grade III                                 0                  0                  0.249
       Grade II                                  0                  0                   
       Grade I                                   0                  0                   
      Lower limbs                                                                       
       Grade V                                   3 (60.0)           11 (64.7)           
       Grade IV                                  2 (40.0)           6 (35.3)            
       Grade III                                 0                  0                  0.880
       Grade II                                  0                  0                   
       Grade I                                   0                  0                   
  Joint                                          2 (40.0)           7 (41.2)           1.000
  Gastrointestinal (dysphagia)                   1 (20.0)           4 (23.5)           1.000
  Pulmonary                                                                             
      Dyspnea                                    1 (20.0)           6 (35.3)           1.000
      Dyspnea (\< 3 months)                      0                  1 (5.9)            \-
      Chest CT                                                                          
      \"Ground glass\"                           1 (20.0)           4 (23.5)           1.000
      Incipient lung disease                     2 (40.0)           5 (29.4)           1.000
      Pulmonary fibrosis                         0                  1 (5.9)            \-
      Creatine phosphokinase (U/L)               167 (103-527)      105 (58-159)       0.330
      Aldolase (U/L)                             15.2 (11.2-22.7)   7.8 (4.0-10.5)     0.067

MDA: melanoma differentiation-associated gene 5.

Data expressed as mean ± standard deviation, median (interquartile range 25% -75%), or percentage (%).

DISCUSSION
==========

The study showed that the frequency of anti-MDA-5 autoantibody in Brazilian patients with DM and clinically amyopathic DM was consistent with that reported in other populations, but with different reactivity from that described in the literature.

The study's strengths include the evaluation of presence of anti-MDA-5 autoantibody in patients with a well-defined diagnosis of DM, based on the criteria proposed by Bohan and Peter^[@r1]^ and thus excluding cases with probable or possible diagnoses. For cases of clinically amyopathic DM, we used the updated definition proposed by Gerami *et al.*^[@r5]^ In addition, unlike previous studies in the literature, we applied rigorous exclusion criteria, for example patients with history of lung disease, tuberculosis, other systemic autoimmune diseases, neoplasms, smoking, and others, since such diseases, comorbidities, or habits could act as confounding factors for the interpretation and association between presence of anti-MDA-5 autoantibody and the clinical presentation of patients with DM or clinically amyopathic DM.

Although this was a retrospective study, the data had been previously standardized and parameterized and were thus trustworthy. In addition, in order to increase the specificity of the ELISA test, we applied a cutoff point of at least three standard deviations to include cases in the study, unlike previous studies such as Labrador-Horrillo *et al.*, ^[@r14]^ who used two standard deviations as their cutoff.

According to the literature, positivity for anti-MDA-5 autoantibody can vary from 4.7 to 13.1% in DM and 10.0 to 18.8% in patients with clinically amyopathic DM.^[@r7],[@r11]-[@r14]^ In the current study, MDA-5 autoantibody was present in 14.7% of patients with DM and 22.7% in clinically amyopathic DM, thus corroborating the rates reported in the literature. Since anti-MDA-5 autoantibody can vary according to disease activity, it is important to note that the current study only included patients with clinical and laboratory activity.^[@r18]-[@r20]^

In patients with classic DM, anti-MDA-5 autoantibody was associated with lower frequency of Raynaud's phenomenon and periungual hyperemia. However, unlike other studies, we did not find an association between this autoantibody and the presence of skin ulcers, for example.^[@r12]-[@r14]^ Further studies are needed to better elucidate the relevance of these associations.

Neither did we observe an association between anti-MDA-5 autoantibody and a clinical presentation similar to anti-synthetase syndrome or its components (e.g., joint and pulmonary involvement). However, Hall *et al.*^[@r12]^ and Labrador-Horrillo *et al.*^[@r14]^ reported a high rate of anti-MDA-5 autoantibody in patients with symptoms suggestive of anti-synthetase syndrome, but without the presence of anti-synthetase autoantibody (e.g., anti-Jo-1 autoantibody). These discrepant data reinforce the presence of wide phenotypical variability among the different populations studied, as well as different anti-MDA-5 autoantibody reactivity according to the study population. Unlike our study, those authors did not mention possible confounding factors that could lead to lung or joint involvement in their series (e.g., overlapping diagnoses, history of smoking, chronic obstructive pulmonary disease (COPD), history of tuberculosis, etc.).^[@r12],[@r14]^

In patients with clinically amyopathic DM we observed a variety of skin lesions, mainly Gottron's sign/papules, heliotrope rash, facial rash, and periungual hyperemia. These were distributed the same way in patients with or without presence of anti-MDA-5 autoantibody. In contrast, studies in the literature reported a strong association between this autoantibody and the skin lesions found in patients with clinically amyopathic DM.^[@r6],[@r8],[@r12]-[@r14]^

Pulmonary involvement in patients with clinically amyopathic DM is relatively common.^[@r6],[@r20]-[@r24]^ Particularly in Japanese and Chinese populations, it has been reported frequently in patients with rapidly progressive interstitial lung disease.^[@r6],[@r20]-[@r24]^ Meanwhile, the prevalence of rapidly progressive interstitial lung disease in clinically amyopathic DM is relatively low in the United States, as in the current study.^[@r25]^

Previous studies also showed a strong association between anti-MDA-5 autoantibody and presence of pulmonary manifestations, which we did not observe in this study.^[@r6],[@r9],[@r14]^ One explanation is that we found a low rate of patients with pulmonary involvement and rapidly progressive dyspnea. These findings in turn may be the consequence of phenotypical diversity in the study sample, as well as the use of strict exclusion criteria, especially for factors related to pulmonary involvement (COPD, smoking, etc.).

As limitations, the study used a cross-sectional design, which prevented establishing a temporal correlation between anti-MDA-5 autoantibody and various independent variables. In addition, lung function tests were not performed in the patients.

CONCLUSIONS
===========

Anti-MDA-5 autoantibody was highly prevalent in patients with DM and clinically amyopathic DM, consistent with findings in other populations, but with different reactivity than described in the literature. The patients in our sample also had different clinical characteristics from those reported in the literature, i.e., without major pulmonary and/or cutaneous involvement and with no similarity to anti-synthetase syndrome.

The study's results can contribute to our understanding of different clinical, phenotypical, laboratory, and demographic characteristics of patients, thus allowing more individualized diagnosis and treatment.
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